C

Corvus Pharmaceuticals
D

CRVS

3.62000
USD
0.12
(3.43%)
مغلق
حجم التداول
26,733
الربح لكل سهم
-0
العائد الربحي
-
P/E
-4
حجم السوق
246,773,449
أصول ذات صلة
A
ALT
0.61000
(11.82%)
5.77000 USD
A
AYTU
-0.08000
(-5.88%)
1.28000 USD
MRNA
MRNA
0.600
(2.22%)
27.590 USD
N
NNVC
-0.05000
(-3.76%)
1.28000 USD
N
NVAX
0.01000
(0.16%)
6.41000 USD
R
RFL
-0.03600
(-2.28%)
1.54000 USD
V
VCEL
1.025
(2.70%)
38.935 USD
V
VXRT
0.01940
(4.52%)
0.44840 USD
المزيد
الأخبار المقالات

العنوان: Corvus Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).